Trial Profile
Open Label Randomized Phase II Trial of Nivolumab + Cabiralizumab (BMS-986227, FPA008) + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial)
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Cabiralizumab (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms GemCaN Trial
- 27 Apr 2023 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 27 Apr 2023 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.
- 05 May 2020 Status changed from recruiting to suspended.